secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280149
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Q3 net loss $11.8M; cash $194.9M funds operations into 2028
-----------------------------------------------------------------

- Net loss of $11.8M for Q3 2025 vs. $13.2M in Q3 2024; R&D spend down to $10.1M.
- Cash and marketable securities $194.9M at Sept 30, 2025; expected runway into 2028.
- Preparing End-of-Phase 2 meeting request to FDA for IPF chronic cough in Q4 2025.
- Phase 3 program for IPF chronic cough planned to start in H1 2026.
- Phase 2b study for refractory chronic cough (RCC) also targeted for H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/0001193125-25-280149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000119312525280149/trvi-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer